spacer
home > white papers > The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing - GE Healthcare Life Sciences
WHITE PAPERS

GE Healthcare Life Sciences

phone + 1 800 526 3593
email cs-us@ge.com
web http://www.gelifesciences.com
email P.O. Box 643065 Pittsburgh, PA 15264-3065 United States of America

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include:

• The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model

• Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint

• The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline

• Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures

• Tighter capital markets that will create heightened scrutiny for all new investment projects
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Horizon Discovery Licenses Biomanufacturing Cell Lines to Centre for Process Innovation (CPI) and National Institute for Bioprocessing Research and Training (NIBRT)


More info >>


White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>


Industry Events

Cell Therapy Manufacturing & Gene Therapy Congress

6-7 December 2017, RAI, Amsterdam

Bringing together 300+ leaders and key influencers from pharma and biotech companies on 6 - 7 December 2017 in Amsterdam, Cell Therapy Manufacturing & Gene Therapy Congress will provide you with the latest advice for driving manufacturing and commercialisation through direct access to transforming innovative research to prosperous cell & gene manufacturing.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement